Combination therapies of HDAC inhibitors and PD-L1 inhibitors
AssigneeHUYABIO International, LLC
InventorsReid P. Bissonnette, Alain Rolland, Mireille Gillings
Life of this patent
Estimating the term…
Abstract
Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
Claims12
A method for treating colorectal cancer in a subject, comprising administering to the subject a therapeutically effective amount of a histone deacetylase inhibitor (HDAC inhibitor) in combination with a PD-L1 antibody, and the HDAC inhibitor is a compound of formula Ia:
A pharmaceutical composition comprising an HDAC inhibitor and a PD-L1 antibody, wherein the HDAC inhibitor is a compound of formula Ia:
A kit comprising an HDAC inhibitor and a PD-L1 antibody, wherein the HDAC inhibitor is a compound of formula Ia:
Dependencies are inferred from the claim text.